Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “TEVA PHARMACEUTICAL INDUSTRIES, LTD.”

302 pharma patents match "TEVA PHARMACEUTICAL INDUSTRIES, LTD." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 302
Index total 30,257
Page 10 / 13

Quick answer

This filtered view shows 302 pharmaceutical patents matching "TEVA PHARMACEUTICAL INDUSTRIES, LTD." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

302 results for “TEVA PHARMACEUTICAL INDUSTRIES, LTD.” · 30,257 patents in full index Clear search

  1. US 7244844

    Reference standard for characterization of rosuvastatin

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jul 17, 2007 · Expires Jul 12, 2027

    granted
  2. US 7235691

    Crystalline forms of modafinil

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jun 26, 2007 · Expires Jun 21, 2027

    granted
  3. US 7196222

    Sertraline hydrochloride form II and methods for the preparation thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 27, 2007 · Expires Mar 22, 2027

    granted
  4. US 7195778

    Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 27, 2007 · Expires Mar 22, 2027

    granted
  5. US 7192588

    Vaccine composition and method of using the same

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 20, 2007 · Expires Mar 15, 2027

    granted
  6. US 7189861

    Processes for preparing amorphous atorvastatin hemi-calcium

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 13, 2007 · Expires Mar 8, 2027

    granted
  7. US 7183272

    Crystal forms of oxcarbazepine and processes for their preparation

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Feb 27, 2007 · Expires Feb 22, 2027

    granted
  8. US 7161012

    Processes for preparing amorphous atorvastatin hemi-calcium

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jan 9, 2007 · Expires Jan 4, 2027

    granted
  9. US 7151183

    Processes for preparing amorphous atorvastatin hemi-calcium

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 19, 2006 · Expires Dec 14, 2026

    granted
  10. US 7148376

    Polymorphic forms of nateglinide

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 12, 2006 · Expires Dec 7, 2026

    granted
  11. US 7144916

    Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 5, 2006 · Expires Nov 30, 2026

    granted
  12. US 7138137

    Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Nov 21, 2006 · Expires Nov 16, 2026

    granted
  13. US 7129358

    Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 31, 2006 · Expires Oct 26, 2026

    granted
  14. US 7126008

    Carvedilol

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 24, 2006 · Expires Oct 19, 2026

    granted
  15. US 7122681

    Desolvation process for the production of atorvastatin hemi-calcium essentially free of bound organic solvent

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 17, 2006 · Expires Oct 12, 2026

    granted
  16. US 7060837

    Method for the purification of lansoprazole

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jun 13, 2006 · Expires Jun 8, 2026

    granted
  17. US 7056942

    Carvedilol

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jun 6, 2006 · Expires Jun 1, 2026

    granted
  18. US 7038060

    Synthesis of 2-butyl-3-(2′-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted May 2, 2006 · Expires Apr 27, 2026

    expired
  19. US 7033582

    Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 25, 2006 · Expires Apr 20, 2026

    expired
  20. US 7022859

    Method for the purification of lansoprazole

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 4, 2006 · Expires Mar 30, 2026

    expired
  21. US 7022881

    Sertraline hydrochloride polymorphs

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 4, 2006 · Expires Mar 30, 2026

    expired
  22. US 6992194

    Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jan 31, 2006 · Expires Jan 26, 2026

    expired
  23. US 6987175

    Processes for preparing clarithromycin polymorphs

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jan 17, 2006 · Expires Jan 12, 2026

    expired
  24. US 6956060

    Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 18, 2005 · Expires Oct 13, 2025

    expired